Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Thousand Oaks, United States. In Int J Biochem Cell Biol, 2013
Binding of myostatin and activin to the ActRIIB receptor complex on muscle cell membrane leads to activation of Smad2/3-mediated transcription, which in turn stimulates FoxO-dependent transcription and enhanced muscle protein breakdown via ubiquitin-proteasome system and autophagy.
Activin receptor signaling: a potential therapeutic target for osteoporosis.
Boston, United States. In Curr Mol Pharmacol, 2012
The binding of activins to activin type IIA (ActRIIA) or type IIB (ActRIIB) receptors induces the recruitment and phosphorylation of an activin type I receptor (ALK4 and/or ALK7), which then phosphorylates the Smad2 and Smad3 intracellular signaling proteins.
Birmingham, United Kingdom. In Cell, 2010
Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB).